We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Panel Wants Tighter Bioequivalence Standards for NTIs
Advisory Panel Wants Tighter Bioequivalence Standards for NTIs
July 29, 2011
An FDA advisory committee recommends tighter bioequivalence standards for generic versions of narrow therapeutic index (NTI) drugs — sometimes called critical dose drugs — as small differences in dosing can lead to dangerous side effects.